secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001558370-23-002835
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Phase 2a zunsemetinib trial for hidradenitis suppurativa fails to meet endpoints
--------------------------------------------------------------------------------

- Study did not meet primary endpoint of change in inflammatory nodule/abscess count at week 12.
- Secondary endpoints including HiSCR-50 also not met; placebo effect higher than in published HS studies.
- Zunsemetinib generally well tolerated; most common AEs: dizziness (16.7%), diarrhea (12.5%), headache (12.5%).
- No serious adverse events or opportunistic infections observed; PK/PD consistent with prior studies.
- CEO notes next data readout from Phase 2b rheumatoid arthritis study is expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023002835/0001558370-23-002835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023002835/acrs-20230306x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer